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Germline Mutation of INI1/SMARCB1 in Familial
Schwannomatosis
Theo J. M. Hulsebos, Astrid S. Plomp, Ruud A. Wolterman, Els C. Robanus-Maandag,
Frank Baas, and Pieter Wesseling
Patients with schwannomatosis develop multiple schwannomas but no vestibular schwannomas diagnostic of neurofi-
bromatosis type 2. We report an inactivating germline mutation in exon 1 of the tumor-suppressor gene INI1 in a father
and daughter who both had schwannomatosis. Inactivation of the wild-type INI1 allele, by a second mutation in exon
5 or by clear loss, was found in two of four investigated schwannomas from these patients. All four schwannomas
displayed complete loss of nuclear INI1 protein expression in part of the cells. Although the exact oncogenetic mechanism
in these schwannomas remains to be elucidated, our findings suggest that INI1 is the predisposing gene in familial
schwannomatosis.
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Schwannomatosis (MIM 162091) is characterized by the
development of multiple spinal, peripheral, and cranial-
nerve schwannomas in the absence of vestibular schwan-
nomas.1 The presence of vestibular schwannomas is di-
agnostic of neurofibromatosis type 2 (NF2 [MIM 101000]).
Molecular analyses identified somatically acquired mu-
tations in the NF2 gene in schwannomas of patients with
schwannomatosis.2–4 However, linkage studies performed
in families affected with schwannomatosis excluded NF2
as the germline-transmissible schwannomatosis gene and
suggested a location of this gene near marker D22S1174,
which is in the region on chromosome 22 centromeric to
NF2.4 In this region is the CABIN1 gene, in which missense
mutations may contribute to the pathogenesis of both
schwannomatosis and NF2.5
We investigated whether INI1—also known as SMARCB1,
hSNF5, and BAF47—is involved in familial schwannom-
atosis. INI1 is an attractive candidate gene, because it is a
tumor-suppressor gene that is located within a short dis-
tance (i.e., !360 kb) of marker D22S1174 (University of
California Santa Cruz [UCSC] Genome Browser). INI1 is a
member of the ATP-dependent SWI-SNF chromatin re-
modeling complex and affects the expression of genes that
regulate cell cycle, growth, and differentiation.6 The in-
volvement of INI1 in schwannoma tumorigenesis has
been investigated in one earlier study, but no mutations
were found in 23 tumors. However, only exons 2–8 of INI1
were examined (i.e., not exons 1 or 9), and it was not
specified whether tumors of patients with schwannoma-
tosis were included.7 Thus far, INI1 is known to be in-
volved in the development of malignant rhabdoid tumors
that typically occur in the brain and kidney of infants.8–
10 Only two families with an INI1 germline mutation, an
exon 4 frameshift mutation,11 and an exon 7 donor splice
site mutation12 have been described in which multiple
generations were affected by malignant (rhabdoid) tumors
in infancy. In both of these families, clear cases of no-
nexpressing obligate carriers of the INI1 mutation were
seen. Recently, INI1 alterations have been reported to oc-
cur in the proximal type of epithelioid sarcomas.13
To determine the possible involvement of INI1 in fa-
milial schwannomatosis, we examined the mutational
status of this gene in constitutional and tumor DNA of a
proband and her father, both of whom fulfill the diag-
nostic criteria for schwannomatosis.14 Additionally, we in-
vestigated INI1 protein expression in these tumors by im-
munohistochemistry. Finally, we sequenced the NF2 gene
to determine whether these neoplasms carried somatically
acquired NF2 mutations as well.
The proband, a 22-year-old female, presented with pain
in her back that had been increasing for 3 years. A mag-
netic resonance imaging (MRI) scan of the lumbar spine
revealed intradural tumors at L1 and L2–L3. After lami-
nectomy, three tumors arising from lumbar spinal nerve
roots were removed and diagnosed histopathologically as
schwannomas. MRI scans of the cervical and thoracic
spine showed multiple intradural, extramedullary lesions
of variable size. The most cranial lesion was at C6–C7.
MRI scans of the brain (1-mm T2 weighted slices and, after
contrast, 3-mm T1 weighted slices) were normal; in par-
ticular, vestibular schwannomas were absent. Three years
after surgery, except for some local numbness in the right
thigh, the patient has not had any more symptoms. As
part of the counseling procedure, the NF2 gene in blood
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Table 1. Primers for Amplification of the INI1 Exons
Exon
Product
Size
(bp)
Primer Sequence
Forward Reverse
1 140 5′-CCC TCC TGA TCC CTC GCA GC-3′ 5′-CGG GCT ACC TCG GAG CCG AT-3′
2 213 5′-CTG CGA CCC TTA TAA TGA GC-3′ 5′-GCG AGT GGT TTT GAA ACA GG-3′
3 195 5′-ACC AGC AGA GTG ACC CAG TG-3′ 5′-AGA GAT GCC CTG GCC AGG AA-3′
4 225 5′-GGA TCA GGT CCT ATA CTG AC-3′ 5′-AAC TAA GGC GGA ATC AGC AC-3′
5 201 5′-TTG CAT ACC TAG GGC TCC GG-3′ 5′-GCC CGA CTG CCT TGT ACC AT-3′
6 277 5′-TGG TGC AAT CTC TTG GCA TC-3′ 5′-TCA GTG CTC CAT GAT GAC AC-3′
7 312 5′-TGG GCT GCA AAA GCT CTA AC-3′ 5′-CGC TCA CAC AGA GAA GTC TT-3′
8 313 5′-ATC CAC TGG GTG CCA GCA GT-3′ 5′-TCT GCC TGG AAA GCC AGG TG-3′
9 200 5′-CCC TGT AGA GCC TTG GGA AG-3′ 5′-GCC TCT GTC CTT GCC AGA AG-3′
NOTE.—Annealing temperature was 60C.
Table 2. Primers for Amplification of the NF2 Exons
Exon
Product
Size
(bp)
Primer Sequence
Forward Reverse
1 225 5′-GGC TAA AGG GCT CAG AGT GC-3′ 5′-CTT CCA CCT CGA CTG TCA CC-3′
2 222 5′-ATT TTT GCT CAC AGT GTC CTT CC-3′ 5′-ACT GGA AAG CTC ACG TCA GCC-3′
3 179 5′-GTC TTT TGC TCT GCA ATT CTG C-3′ 5′-AGA ACT GGG GGG TAG CCT TGA-3′
4 170 5′-AGT ATC ATG TCT CCC TTG TTG CT-3′ 5′-CCA TGA CCC AAA TTA ACG CCC A-3′
5 159 5′-CTT TAG AAT CTC AAT CGC CTG C-3′ 5′-CCA CAT ATC TGC TAT GTC TTC CT-3′
6 261 5′-GTG ACT ATC TCC CTG GGT GTA-3′ 5′-CCC CAT AAA GGA ATG TAA ACC AAC-3′
7 180 5′-GAT TTG GTG CCC ACC CGC TC-3′ 5′-ACA CAA GGA GCT CAG AGA GGT T-3′
8 187 5′-GTA GCT GTT CTT ATT GGA TCC AC-3′ 5′-CAT CTG CAG TAC ACA CAT GTC C-3′
9 256 5′-GTG TGG TTG CGC ATT TGT GGA A-3′ 5′-CAC AAG ATG TCA CTC TGA TAT CC-3′
10 230 5′-TGG GCC AGT AGG CAG TGA AG-3′ 5′-AGG ACT GAC CAC ACA GTG ACA-3′
11 214 5′-CTC GAG CCC TGT GAT TCA ATG-3′ 5′-AGT CCC CAA GTA GCC TCC TG-3′
12 286 5′-CCC ACT TCA GCT AAG AGC ACT-3′ 5′-CTC CTC GCC AGT CTG GTG C-3′
13 203 5′-ACC TGC CCT CTT CTG TGA AGC-3′ 5′-AGA ACA TCA CCA GGA CTA AGG C-3′
14 213 5′-TGA CCC AAG CTC CTA ATC CGA-3′ 5′-AGT CTA GTT CAC AGC TGC CCA-3′
15 254 5′-GTC TCA CTG TCT GCC CAA GC-3′ 5′-GGT CCT GAT CAG CAA AAT ACA AG-3′
16 188 5′-CAT TTT GCA ATG GCA CTT ATG GC-3′ 5′-CGG GTT AGT ATC ACA GAG GGC-3′
17 268 5′-CTC TCA GCT TCT TCT CTG CTT T-3′ 5′-ACA GGG TCG TAG TTC AAG GCA-3′
NOTE.—Annealing temperature was 54C.
DNA of the patient was sequenced in the laboratory of Dr.
Olschwang (Institut Paoli-Calmettes, Marseilles), but no
mutation was found. The father of the proband had a
history of diabetes mellitus and had surgery at the age of
∼35 years because of Wolff-Parkinson-White syndrome.
When he was 49 years of age, subcutaneous tumors were
removed from his right thumb, right index finger, and the
first web space of his left hand and were diagnosed his-
topathologically as schwannomas. In subsequent years,
additional schwannomas were removed from his right up-
per arm and right thumb, and two seborrheic keratosis
lesions from his forehead. A CT scan of the lumbar spine
that was performed because of a herniated intervertebral
disc when he was 50 years old revealed no tumors, nor
did an MRI scan of the brain (3-mm T2 weighted slices
and, after contrast, 3-mm T1 weighted slices) that was
performed because of a mild cerebrovascular accident
when he was 51 years old. In both the father and his
daughter (who was his only child), the dermatologist and
ophthalmologist did not find other signs of neurofibro-
matosis. The father died at the age of 57 years from cardiac
arrest. An autopsy was not performed. In both patients,
hearing loss, tinnitus, and balance dysfunction were ab-
sent. The parents, one brother, and one sister of the father
had no obvious signs of schwannomatosis.
Informed consent of the proband and her mother was
obtained for using their body materials and those of the
deceased father. Frozen tumor material was available
from one schwannoma from the sacral region of the
proband. Peripheral blood was taken from the mother.
From the father, formalin-fixed and paraffin-embedded
tissue was available from three schwannomas (right index
finger, right upper arm, and right thumb) and from one
seborrheic keratosis lesion. Genomic DNA was extracted
from blood and tissues by use of commercially available
kits (Qiagen). The INI1 and NF2 genes were sequenced by
use of genomic DNA as substrate for amplification by PCR.
Primer sequences for mutation analysis of the 9 INI1 exons
and the 17 NF2 exons were kindly provided by, respec-
tively, Dr. J. A. Biegel15 and Dr. S. Olschwang (personal
communication) and are listed in tables 1 and 2, respec-
tively. Sequence reactions were performed using ABI Big
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Figure 1. Sequence analysis of parts of INI1 in blood and tissues of proband and parents. The CrT mutation in exon 1 of INI1 was
detected in DNA from blood and from the schwannoma of the sacral region of the proband (a and b). It was also detected in DNA from
the seborrheic keratosis lesion and from the schwannomas of the right thumb, right index finger, and right upper arm of the father
(c–f) but not in blood DNA of the mother (g). An additional CrT mutation in exon 5 of INI1 was detected in DNA of the right thumb
tumor of the father (i) but not in DNA of his seborrheic keratosis lesion (h).
Dye v3.1 chemistry, and the products were sequenced
with an ABI 3730 capillary system (Applied Biosys-
tems). Sequences were analyzed with CodonCode Aligner
(CodonCode).
To search for a constitutional mutation in the INI1 gene,
the nine exons of this gene were sequenced. As shown in
figure 1, a heterozygous CrT mutation in codon 12 of
exon 1 (c.34CrT in the mRNA [GenBank accession num-
ber U04847]) was identified in blood DNA of the proband
and in DNA of the seborrheic keratosis lesion of her father
(which was used as a source of constitutional DNA because
blood of the deceased father was not available), as well as
in DNA of all four schwannomas that were available for
further analysis (one from the proband and three from
her father), but not in blood DNA of the clinically unaf-
fected mother. This mutation converts a glutamine codon
into a stop codon (p.Q12X), resulting in premature ter-
mination of translation of the INI1 protein at that posi-
tion. Additionally, DNA extracted from the right-upper-
arm lesion of the father revealed a strongly decreased peak
height for the wild-type C allele, suggesting partial loss of
the normal INI1 allele, whereas, in DNA from the tumor
of his right thumb, an additional, heterozygous CrT mu-
tation in codon 182 of exon 5 was found (c.544CrT),
which also converts a glutamine codon into a stop codon
(p.Q182X). No additional mutations or clear losses were
found in the third schwannoma of the father nor in the
tumor of the proband, although the small decrease in peak
height for the wild-type C allele may suggest some loss of
the normal INI1 allele in both tumors. Since somatically
acquired mutations have been reported to accumulate in
the NF2 gene in schwannomas of patients with schwan-
nomatosis,2–4 we determined the nucleotide sequence of
the 17 exons of this gene in DNA extracted from the tu-
mors of both the proband and the father. We found no
NF2 mutations in these tumors.
The truncating mutations in exons 1 and 5 of INI1 are
both predicted to cause mRNA decay and loss of INI1
protein expression by the mutated allele.16 We studied
the effect of these mutations on the INI1 protein level
by immunohistochemical analysis performed using an
INI1/BAF47 antibody (BD Transduction Laboratories). For
this purpose, 5-mm histological sections of formalin-fixed,
paraffin-embedded tumor-tissue sections were dewaxed in
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Figure 2. Immunohistochemical INI1/BAF47 staining of schwannomas of the proband (a, sacral region) and her father (b, right index
finger; c, right thumb; d, right upper arm), as well as of a seborrheic keratosis lesion of the father (e) and of a schwannoma of a
patient not affected with schwannomatosis (f). Note the mosaic staining of cell nuclei in schwannomas of both the proband and her
father. In contrast, the nuclei of cells in the tumor vessels in panels a–d (arrowheads), as well as the nuclei in a seborrheic keratosis
lesion of the father and in a schwannoma in a patient unaffected with schwannomatosis, all show unequivocal staining. The arrow in
panel c indicates palisading of tumor cell nuclei in a Verocay body. Original magnification #200.
xylol and rehydrated through alcohol. Endogenous per-
oxidase was blocked with 3% hydrogen peroxide. The sec-
tions were pretreated by microwave heating, cooled down
to room temperature, and incubated for 60 min with the
INI1/BAF47 antibody. After incubation with the secondary
antibody (poly-HRP-GAM/R/R IgG [Immunologic]), the
staining procedure was finished using DAB. The sections
were counterstained with hematoxylin (1 min), dehy-
drated, and cover slipped. All four schwannomas from this
family showed a consistent mosaic staining pattern for
INI1, with a mixture of negative and positive cell nuclei
(fig. 2a–d). This pattern was maintained after a fourfold
concentrated INI1-antibody solution was applied to the
sections (dilution 1:60 instead of 1:250 [data not shown]).
The seborrheic keratosis lesion of the father (fig. 2e) and
the schwannomas of five different patients unaffected
with schwannomatosis—including vestibular and soft-tis-
sue schwannomas and a schwannoma from a patient with
multiple schwannomas (fig. 2f)—demonstrated abundant
and uniform nuclear staining in all cells.
Our findings suggest that INI1 germline mutations pre-
dispose individuals to familial schwannomatosis. Earlier
linkage studies by others in families affected with schwan-
nomatosis excluded NF2 as the schwannomatosis gene
and pointed to the location of this presumptive gene in
a region nearby marker D22S1174 (multipoint LOD score
of 6.60), which is centromeric to NF2 on chromosome 22.4
We considered INI1 an attractive candidate for represent-
ing the familial schwannomatosis gene, because it is a
tumor-suppressor gene and it is located within short dis-
tance of D22S1174 (UCSC Genome Browser). We therefore
sequenced this gene in constitutional and tumor DNA of
the proband and her father, who both suffered from clin-
ically proven schwannomatosis. Because an inactivating
CrT mutation was present in exon 1 of the INI1 gene, not
only in all schwannomas of these patients but also in
blood of the proband and in a seborrheic keratosis lesion
of her father, we conclude that this mutation represents
a germline mutation.
According to Knudson’s two-hit hypothesis for the on-
cogenesis of tumors, this germline mutation may very well
represent the first hit in tumor development.17 The second
hit that leads to the formation of schwannomas should
then involve the wild-type INI1 allele and could theoret-
ically consist of somatic mutation, loss of heterozygosity
(LOH), or silencing by other means, such as epigenetic
modification. Indeed, using sequence analysis, we de-
tected an additional truncating CrT mutation in exon 5
in part of the cells in one schwannoma and partial loss
of the wild-type allele in another tumor of the father. In
accordance with these observations, these schwannomas
showed a mosaic INI1 staining pattern, with a mixture of
negative and positive cell nuclei. This pattern was also
present in the two schwannomas without an easily de-
tectable second hit, suggesting that silencing of the wild-
type INI1 allele occurred by other mechanisms, as has been
suggested for rhabdoid tumors without INI1 mutations.10
The mosaic staining pattern seems to be characteristic of
schwannomas of patients with schwannomatosis, as we
noted uniform and unequivocal nuclear staining in the
seborrheic keratosis lesion of the father and in various
schwannomas of patients without schwannomatosis.
Clearly, our immunohistochemical findings corroborate
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the involvement of INI1 in the oncogenesis of schwan-
nomas in our patients with schwannomatosis.
Further elucidation of the exact oncogenetic role of INI1
is warranted. It is unknown at present how INI1 germline
mutations can predispose infants to malignant rhabdoid
tumors10–12 and patients with familial schwannomatosis
to schwannomas. Since, to our knowledge, INI1 germline
mutations in exon 1 have not been reported before, one
possible explanation is that different INI1 mutations are
associated with different tumor types. Furthermore, as sug-
gested by others,11 individuals with a germline INI1 mu-
tation may have an increased risk for developing a malig-
nant rhabdoid tumor especially in early childhood. Later
in life, this risk may decrease, but germline INI1 mutations
may then predispose individuals to the development of
other tumors, such as schwannomas. Finally, additional
somatic inactivation of NF2 or other genes may play a
role in the development of schwannomas of patients with
schwannomatosis. Although we were unable to detect NF2
aberrations in our patients, others found NF2 mutation
and loss in a considerable fraction of the investigated tu-
mors.2–4 In contrast with malignant rhabdoid tumors and
the proximal type of epithelioid sarcomas that generally
show complete loss of nuclear INI1 staining,9,10,13 the
schwannomas of our patients with schwannomatosis
showed a mosaic staining pattern of cell nuclei, indicating
complete loss of INI1 protein expression in part of the
cells. Additional immunohistochemical INI1 and S100
stainings on serial sections of the tumors showed that the
majority of cells are S100 positive, corroborating the
Schwann cell nature of these cells (data not shown). As
has been described for neurofibromas,18,19 the tumors in
our patients may be comprised of different (Schwann) cell
populations, the cells that completely lost INI1 protein
expression being the true neoplastic cells.
In conclusion, this is the first report of a germline mu-
tation that predisposes individuals to familial schwan-
nomatosis. The mutation is located in the INI1 gene, a
tumor-suppressor gene that is also involved in the on-
cogenesis of tumors with a completely different histology
and prognosis. Further studies are needed to determine
whether the inactivation of the INI1 gene is the cause of
tumor formation in other cases of familial and sporadic
schwannomatosis as well and to elucidate the exact on-
cogenetic mechanisms and functional consequences of
INI1 inactivation in these and other tumors.
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